REaCT Integrated Consent Model to Compare Two Standard of Care Regimens

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The Integrated Consent Model is being increasingly used internationally to improve patient care. In this feasibility study we will explore whether the model is feasible in practice; and whether it can be used to increase the number of physicians and patients who take part in clinical trials, and address the critical issue around the optimal febrile neutropenia prevention by randomizing eligible patients to either G-CSF or ciprofloxacin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute
• Treatments: Ciprofloxacin; Lenograstim; Sargramostim

Criteria

Inclusion Criteria:

• Histologically confirmed primary breast cancer

• Planned TC chemotherapy

• ≥19 years of age

• Able to provide verbal consent

• Willing to complete a survey

Exclusion Criteria:

• Contraindication to either Ciprofloxacin or G-CSF